MedTrace Logo

Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors

NCT07139067 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-08-24

No results posted yet for this study

Summary

A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.

Conditions

  • Advanced Solid Tumor Cancer

Interventions

BIOLOGICAL

YK1101 cells

Drug: Fludarabine + Cyclophosphamide

Sponsors & Collaborators

  • Yingkai Saiwei（Beijing）Biotechnology Co., Ltd

    collaborator UNKNOWN

  • Peking University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-27
Primary Completion
2026-07-01
Completion
2028-07-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07139067 on ClinicalTrials.gov